DAIC

JUNE 4, 2024

milla1cf Tue, 06/04/2024 - 20:54 June 4, 2024 — HeartFlow, a leader in cardiovascular healthcare technology, is pleased to announce a key Medicare policy development, which should allow for future expanded patient access to their Plaque Analysis product.

Medicare 104

Medicare Plaque Reimbursement Cardiovascular Disease 104

DAIC

JULY 18, 2024

a leader in non-invasive artificial intelligence (AI) heart care solutions, introduced the next generation HeartFlow Plaque Analysis with an interactive experience. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C. F.A.C.C.

Coronary Artery Disease 111

Coronary Artery Disease Plaque Technology Medicare 111

DAIC

OCTOBER 16, 2024

15 , 2024 — Four of the seven Medicare Administrative Contractors (MACs) have released final local coverage determinations (LCD) for AI-Coronary Plaque Analysis (AI-CPA). tim.hodson Wed, 10/16/2024 - 12:36 Oct. The four contractors for the U.S.

CMS 52

CMS Medicare Plaque Chest Pain 52

DAIC

JUNE 18, 2024

The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. This restores the vessel viability and hemodynamic modulation by returning pulsatility, compliance, adaptive blood flow volume, and plaque stabilization and regression.

Coronary Artery Disease 105

Coronary Artery Disease Technology Stent Stents 105

DAIC

JANUARY 3, 2024

3 HeartFlow’s FFR CT Analysis is covered by Medicare and for >99% of commercially insured lives. We've experienced a year of notable accomplishments and growth including the expansion of our product portfolio with Plaque Analysis and RoadMap Analysis. said John Farquhar, Chief Executive Officer at HeartFlow.

Coronary Artery Disease 59

Coronary Artery Disease Chest Pain Plaque Technology 59

DAIC

DECEMBER 5, 2024

The company’s advanced non-invasive computed tomography (CT) imaging technology enables comprehensive phenotyping of coronary artery disease, grounded in scientific research based on millions of medical images. Until Cleerly, healthcare providers have had no way to easily and completely assess plaque burden in a non-invasive manner.

Coronary Artery Disease 52

Coronary Artery Disease Medicare Plaque Technology 52

DAIC

MAY 8, 2024

2-4 HeartFlow’s non-invasive FFR CT technology has emerged as a leading frontline strategy for accurately diagnosing hemodynamically significant coronary lesions in patients suspected of having CAD. Longitudinal assessment of safety of FEMOROPOPLITEAL endovascular treatment with paclitaxel-coated devices among Medicare beneficiaries.”

Coronary Artery Disease 111

Coronary Artery Disease Chest Pain Ischemia Myocardial Infarction 111